Press Space to continue
Our model wasn’t actually trained on osteosarcoma
Press Space to continue
Sophont CEO @iScienceLuvr reveals how Holon-S1 matched a medical team's findings from expensive molecular tests in a rare bone cancer case, using just a biopsy slide: "We looked at a patient with a rare type of bone cancer called osteosarcoma. Our model wasn’t actually trained on osteosarcoma, but it was able to extract a lot of biological insights that this patient’s medical team had also observed. That medical team had utilized very expensive molecular tests." "We were able to identify this…
iScienceLuvr@iScienceLuvr4d ago
Cancer patients with the same diagnosis often have very different tumor biology. Molecular testing can reveal underlying differences, but that's slow and expensive. Introducing Holon-S1, our platform to predict genes and biomarkers from routine pathology slides. • beats two other models at predicting spatial gene activity in a controlled comparison • has identified potentially novel biomarkers in breast cancer and colon cancer • evaluated across 16 organ types and more than 15 scanners, using slides from both formalin-fixed, paraffin-embedded and fresh-frozen tissue. We believe Holon-S1 has the potential to help researchers find new biomarkers in slides they already have, discover treatment targets, and bring more personalized cancer care within reach!
View